share_log

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference

Pacira BioSciences將參加巴克萊第26屆年度全球醫療保健會議的爐邊談話
Pacira BioSciences ·  03/06 00:00

TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference at 1:35 PM ET on Wednesday, March 13, 2024 in Miami. Live audio of the event can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

佛羅里達州坦帕,2024 年 3 月 6 日(GLOBE NEWSWIRE)— Pacira Biosciences, Inc 納斯達克股票代碼:PCRX)今天宣佈,它將參加由分析師主導的巴克萊26指數爐邊談話第四 年度全球醫療保健會議將於美國東部時間2024年3月13日星期三下午 1:35 在邁阿密舉行。可以通過訪問公司網站的 “活動” 頁面訪問該活動的現場音頻 investor.pacira.com。網絡直播的重播也將在活動結束後的兩週內播出。

About Pacira

關於 Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioverao, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Pacira BioSciences, Inc.(納斯達克股票代碼:PCRX)致力於爲儘可能多的患者提供非阿片類藥物選擇,以重新定義阿片類藥物僅作爲救援療法的作用。Pacira 有三種處於商業階段的非阿片類藥物療法:EXPAREL(布比卡因脂質體可注射混懸液),一種長效局部鎮痛藥,目前獲准用於浸潤、筋膜平面阻滯,並作爲用於術後疼痛管理的斜肌間臂叢神經阻滯;ZILRETTA(曲安奈德丙酮緩釋注射混懸液),一種緩釋的關節內注射適用於治療骨關節炎膝蓋疼痛;以及 ioverao,一種新型的手持式設備,可使用以下方法即時、長效、無藥物地控制疼痛對目標神經施加精確、可控的低溫劑量。要了解有關Pacira的更多信息,包括減少對阿片類藥物的過度依賴的企業使命,請訪問 www.pacira.com

Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com

公司聯繫人:Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論